Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Gynecology | Oncology | Pharmacy | Journal

Back to Journal Articles

Adding Zoledronic Acid Improves Breast CA Survival

Last Updated: June 06, 2011.

 

Combination of zoledronic acid and tamoxifen or anastrozole improves disease-free survival

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Adding zoledronic acid to either anastrozole or tamoxifen improves disease-free survival in women with endocrine-receptor-positive breast cancer who are receiving adjuvant endocrine therapy, according to a study published online June 4 in The Lancet Oncology.

MONDAY, June 6 (HealthDay News) -- Adding zoledronic acid to either anastrozole or tamoxifen improves disease-free survival in women with endocrine-receptor-positive breast cancer who are receiving adjuvant endocrine therapy, according to a study published online June 4 in The Lancet Oncology.

Michael Gnant, M.D., from the Medical University of Vienna in Austria, and colleagues investigated the effect of zoledronic acid on long-term clinical efficacy and disease-free survival in 1,803 premenopausal women with endocrine-receptor-positive breast cancer who were receiving adjuvant endocrine therapy (goserelin) and either tamoxifen or anastrozole. A total of 453 patients were randomly assigned to receive anastrozole alone, while 450 received tamoxifen alone, 450 received anastrozole with zoledronic acid, and 450 received tamoxifen with zoledronic acid, for three years. Participants were followed up for an average of 62 months. Disease-free survival was the primary end point studied. Results were adjusted for eight prognostic variables, and analysis was by intention to treat.

The investigators identified 186 disease-free survival events at follow-up more than two years after completion of treatment. Treatment with zoledronic acid was significantly associated with a reduced number of disease-free survival events (hazard ratio [HR], 0.68), but there was no significant difference between the anastrozole and tamoxifen groups. Zoledronic acid did not significantly impact on the risk of mortality. For patients treated with tamoxifen alone or anastrozole alone, there was no difference in the disease-free survival, but overall survival was worse for those treated with anastrozole alone (HR, 1.75).

"These data show persistent benefits with zoledronic acid and support its addition to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer," the authors write.

Several authors disclosed financial relationships with the pharmaceutical industry, including AstraZeneca and Novartis, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: ASCO: Delayed Chemo Worsens Colorectal Cancer Survival Next: ASCO: Childhood Cancer Tied to Long-Term Cancer Risk

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.